Plasma amyloid levels and the risk of AD in normal subjects in the Cardiovascular Health Study

2008162 citationsJournal Articlegreen Open Access

Authors

Oscar L. López · University of Nevada, Las Vegas

Lewis H. Kuller · University of Nevada, Las Vegas

P. D. Mehta · New York State Office for People With Developmental Disabilities

James T. Becker · University of Nevada, Las Vegas

H. Michael Gach · University of Nevada, Las Vegas

Robert A. Sweet · University of Nevada, Las Vegas

Yue‐Fang Chang

Abstract

Plasma A beta levels are affected by age and by systemic and CNS vascular risk factors. After controlling for these conditions, A beta-40 and A beta 1-42 are weak predictors of conversion to Alzheimer disease (AD) in normal subjects and are only weakly associated with AD in cross-sectional analysis. Consequently, plasma levels of A beta do not seem to be useful biomarkers for AD.

Topics & Keywords

Alzheimer's disease research and treatments Dementia and Cognitive Impairment Research Advanced Glycation End Products research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Neurology

Volume 70, Issue 19, pp. 1664-1671

DOI: 10.1212/01.wnl.0000306696.82017.66

Field-Weighted Citation Impact: 6.23